RELATION BETWEEN LOW SERUM TESTOSTERONE AND PROSTATE CANCER BEHAVIOR
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i7.48143Keywords:
Prostate cancer, Serum testosterone, Elderly men, Behavior, TestosteroneAbstract
Objectives: Prostate cancer is intensifying globally, including Asian countries also. There are a numerous arguments is still going on in concerning the connection among endogenous testosterone levels and prostate ailments. The present research was performed to recognize the assessment of serum testosterone in identifying the threat and prostate cancer incidences.
Methods: Hundred cases were registered in the research, among that, the cases showing low testosterone value (<250 ng/dL) was considered A Group and cases with normal testosterone value (>250 ng/dL) was considered B Group. All cases those went radical prostatectomy were followed for post-operatively with histopathological analysis and variables, namely, Post-operative Gleason grade, pathological tumor status, pathological node status, surgical margin status, extracapsular extension of tumor, seminal vesicle invasion, and matched among groups. Variables were completed with the Student’s t-test; p<0.05 was considered statistically significant.
Results: Serum testosterone levels as found to be reduced among 74% and regular among 34% prostate cancer cases. Patients in Group A showed greater complete tumor stage, advanced nodal stage, and widespread metastases on scientific assessment associated with Group B.
Conclusion: All the elderly men aged 60 and more should be screened of for serum testosterone levels for timely prostate carcinoma diagnosis and for better prognosis in the management.
Downloads
References
Paunikar VM, Barapatre SA. Relationship between endogenous testosterone and prostate carcinoma. J Fam Med Prim Care 2022;11:3735-9. doi: 10.4103/jfmpc.jfmpc_2349_21. PMID 36387691, PMCID PMC9648326
Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages 20-69;an autopsy study of 249 cases. In vivo. 1994;8:439-43. PMID 7803731
Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-60. doi: 10.1200/JCO.2005.03.1492, PMID 16278466
Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and vitamin D receptor gene polymorphism and risk of prostate cancer in men with benign prostatic hyperplasia. Br J Cancer 2003;88:928-32. doi: 10.1038/sj.bjc.6600825, PMID 12644831
Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in Japanese population. Cancer Res 2000;60:305-8. PMID 10667581
David MK, Leslie SW. Prostate specific antigen. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. doi: 10.3322/caac.21492, PMID 30207593
Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054-61. doi: 10.1001/ jama.2015.14905, PMID 26575061
Albuquerque GA, Guglielmetti GB, Barbosa JA, Pontes J Jr., Fazoli AJ, Cordeiro MD, et al. Low serum testosterone is a predictor of high-grade disease in patients with prostate cancer. Rev Assoc Med Bras (1992) 2017;63:704-10. doi: 10.1590/1806-9282.63.08.704, PMID 28977109
Arunprasad K, Chandramohan V. Association between low serum testosterone and prostate cancer behaviour. IJCMR 2018;5:H1-4. doi: 10.21276/ijcmr.2018.5.8.3
Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: A review of the continuing controversy. J Urol 2015;193:403-13. doi: 10.1016/j.juro.2014.07.123, PMID 25260832
Morgentaler A. Turning conventional wisdom upside-down: Low serum testosterone and high-risk prostate cancer. Cancer 2011;117:3885-8. doi: 10.1002/cncr.25975, PMID 21365620
Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-6. PMID 8968017
Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449-53. doi: 10.1016/S0022-5347(01)62922-7, PMID 9679896
Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179-82. doi: 10.1002/pros.10140, PMID 12386917
Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52-8. doi: 10.1002/pros.1046, PMID 11304729
Morgentaler A 3rd, Conners WP. Testosterone therapy in men with prostate cancer: Literature review, clinical experience, and recommendations. Asian J Androl 2015;17:206-11. doi: 10.4103/1008- 682X.148067, PMID 25652633
Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-7. doi: 10.1016/S0022-5347(05)67812-3, PMID 10687985
Published
How to Cite
Issue
Section
Copyright (c) 2023 Pareshchandramajhi Chandra Majhi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
